![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
J Jakubik, L Bacakova, EE el-Fakahany and S Tucek
Institute of Physiology, Academy of Sciences of the Czech Republic, Prague.
The neuromuscular blocking drug alcuronium was found earlier to increase the affinity of muscarinic receptors for methyl-N-scopolamine (NMS). This effect could be observed in some but not in other tissues. Subtype selectivity of the positive allosteric action of alcuronium was now investigated in radioligand binding experiments in Chinese hamster ovary (CHO) cells stably transfected with the genes encoding the M1-M5 subtypes of muscarinic receptors. Alcuronium had a particularly high affinity for the M2 receptor subtype (Kd = 0.6 microM) and its affinity for muscarinic receptor subtypes diminished in the order M2 > M4 = M3 > M1 > M5. Alcuronium allosterically increased the binding of (3H)NMS to membranes containing receptors of the M2 (cooperativity factor alpha = 0.38) and M4 subtypes (alpha = 0.72) and inhibited the binding of (3H)NMS to membranes containing receptors of the M1, M3 and M5 subtypes (alpha = 3.35-4.35). The positive effects of alcuronium could also be observed in experiments with (3H)NMS binding to intact whole cells, indicating that the positive allosteric action of alcuronium occurs by alcuronium binding to receptor domains that are accessible from the extracellular space. Alcuronium diminished the affinity for (3H)quinuclidinyl benzilate [(3H)QNB] at all five subtypes of muscarinic receptors and slowed down the dissociation of both (3H)NMS and (3H)QNB; its decelerating effect on radioligand dissociation was most pronounced at the M2 receptor subtype. Differences between the effects of alcuronium on individual muscarinic receptor subtypes are apparently responsible for differences between the allosteric effects of alcuronium on muscarinic receptors in various tissues that had been described previously.
This article has been cited by other articles:
|
|
 |
|
  P. Michal, E. E. El-Fakahany, and V. Dolezal Muscarinic M2 Receptors Directly Activate Gq/11 and Gs G-Proteins J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 607 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Lanzafame, P. M. Sexton, and A. Christopoulos Interaction Studies of Multiple Binding Sites on M4 Muscarinic Acetylcholine Receptors Mol. Pharmacol., August 1, 2006; 70(2): 736 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jakubik, A. Krejci, and V. Dolezal Asparagine, Valine, and Threonine in the Third Extracellular Loop of Muscarinic Receptor Have Essential Roles in the Positive Cooperativity of Strychnine-Like Allosteric Modulators J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 688 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Avlani, L. T. May, P. M. Sexton, and A. Christopoulos Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1062 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jakubik, S. Tucek, and E. E. El-Fakahany Allosteric Modulation by Persistent Binding of Xanomeline of the Interaction of Competitive Ligands with the M1 Muscarinic Acetylcholine Receptor J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1033 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Krejci and S. Tucek Changes of Cooperativity between N-Methylscopolamine and Allosteric Modulators Alcuronium and Gallamine Induced by Mutations of External Loops of Muscarinic M3 Receptors Mol. Pharmacol., October 1, 2001; 60(4): 761 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ellis and M. Seidenberg Interactions of Alcuronium, TMB-8, and Other Allosteric Ligands with Muscarinic Acetylcholine Receptors: Studies with Chimeric Receptors Mol. Pharmacol., April 13, 2001; 58(6): 1451 - 1460. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Jakubik and J. Wess Use of a Sandwich Enzyme-linked Immunosorbent Assay Strategy to Study Mechanisms of G Protein-coupled Receptor Assembly J. Biol. Chem., January 15, 1999; 274(3): 1349 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jakubík and T. Haga Effects of an Agonist, Allosteric Modulator, and Antagonist on Guanosine-gamma -[35S]thiotriphosphate Binding to Liposomes with Varying Muscarinic Receptor/Go Protein Stoichiometry Mol. Pharmacol., November 1, 1998; 54(5): 899 - 906. [Abstract] [Full Text]
|
|
|
|
|
|
C. Tränkle, I. Andresen, G. Lambrecht, and K. Mohr M2 Receptor Binding of the Selective Antagonist AF-DX 384: Possible Involvement of the Common Allosteric Site Mol. Pharmacol., February 1, 1998; 53(2): 304 - 312. [Abstract] [Full Text]
|
|
|
|
|
|
A. Lanzafame, A. Christopoulos, and F. Mitchelson Three Allosteric Modulators Act at a Common Site, Distinct from that of Competitive Antagonists, at Muscarinic Acetylcholine M2 Receptors J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 278 - 285. [Abstract] [Full Text]
|
|
|
|
|
|
J. Jakubík and E. E. El-Fakahany Positive Cooperativity of Acetylcholine and Other Agonists with Allosteric Ligands on Muscarinic Acetylcholine Receptors Mol. Pharmacol., July 1, 1997; 52(1): 172 - 179. [Abstract] [Full Text]
|
|
|
|
|
|
A. U. Höglund and H. A. Baghdoyan M2, M3 and M4, but not M1, Muscarinic Receptor Subtypes are Present in Rat Spinal Cord J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 470 - 477. [Abstract] [Full Text]
|
|
|
|
|
|
C. Tränkle and K. Mohr Divergent Modes of Action among Cationic Allosteric Modulators of Muscarinic M2 Receptors Mol. Pharmacol., April 1, 1997; 51(4): 674 - 682. [Abstract] [Full Text]
|
|
|
|
|
|
J. Jakubik, E. E. El-Fakahany, and S. Tucek Evidence for a Tandem Two-site Model of Ligand Binding to Muscarinic Acetylcholine Receptors J. Biol. Chem., June 16, 2000; 275(25): 18836 - 18844. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
